X

Trial Profile

Pilot Integrated Biomarker Study of VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Resectable Metastatic Melanoma

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 21 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Pepinemab (Primary)
Indications Malignant melanoma
Focus Biomarker; Pharmacodynamics

Most Recent Events

11 Sep 2024 Results presented at the CRI-ENCI: 8th Annual International Cancer, Immunotherapy Conference
22 Feb 2024 Planned End Date changed from 31 Dec 2031 to 15 Dec 2032.
31 Oct 2023 According to a Vaccinex media release, data from this study will be presented at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com